VALSARTAN AND HYDROCHLOROTHIAZIDE Drug Patent Profile
When do Valsartan And Hydrochlorothiazide patents expire, and what generic alternatives are available?
Valsartan And Hydrochlorothiazide is a drug marketed by Alembic, Amneal Pharms, Apotex Inc, Aurobindo Pharma Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Sciegen Pharms, Watson Labs Teva, and Zydus Lifesciences. and is included in eleven NDAs.
The generic ingredient in VALSARTAN AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; valsartan. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VALSARTAN AND HYDROCHLOROTHIAZIDE?
- What are the global sales for VALSARTAN AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for VALSARTAN AND HYDROCHLOROTHIAZIDE?
Summary for VALSARTAN AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 16 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 44 |
| Patent Applications: | 270 |
| What excipients (inactive ingredients) are in VALSARTAN AND HYDROCHLOROTHIAZIDE? | VALSARTAN AND HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | VALSARTAN AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for VALSARTAN AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Farma de Colombia SA | Phase 3 |
| Damanhour University | N/A |
| Tehran University of Medical Sciences | Phase 3 |
Pharmacology for VALSARTAN AND HYDROCHLOROTHIAZIDE
| Drug Class | Angiotensin 2 Receptor Blocker Thiazide Diuretic |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for VALSARTAN AND HYDROCHLOROTHIAZIDE
Valsartan and Hydrochlorothiazide Market Dynamics, Patent Status, and Financial Trajectory
Valsartan and hydrochlorothiazide is a mature, fully generic antihypertensive combination marketed in the United States under the former reference brand Diovan HCT. Its commercial profile is driven by prescription volume, pharmacy-channel pricing, manufacturing efficiency, and supply reliability rather than patent exclusivity. The combination has low strategic value as a branded product but remains commercially relevant for generic manufacturers because it combines a high-volume angiotensin receptor blocker with an inexpensive thiazide diuretic.
What is the current FDA status of valsartan and hydrochlorothiazide?
Valsartan and hydrochlorothiazide is FDA-approved for hypertension in fixed-dose tablets. The branded reference product is Diovan HCT, originally developed by Novartis. FDA-approved strengths include combinations of valsartan and hydrochlorothiazide such as 80/12.5 mg, 160/12.5 mg, 160/25 mg, and 320/25 mg, subject to product-specific labeling.
The product is regulated as a small-molecule prescription drug. It is not a biologic and does not face biosimilar substitution issues.
| Item | Status |
|---|---|
| Active ingredients | Valsartan and hydrochlorothiazide |
| Therapeutic class | Angiotensin II receptor blocker plus thiazide diuretic |
| Main indication | Hypertension |
| Reference brand | Diovan HCT |
| Original sponsor | Novartis |
| FDA pathway for generics | Abbreviated New Drug Application, or ANDA |
| Biosimilar exposure | None |
| Current market structure | Generic-dominated |
| Primary commercial risk | Price erosion and manufacturing competition |
FDA labeling states that valsartan blocks angiotensin II at the AT1 receptor, while hydrochlorothiazide increases renal sodium and water excretion. The combination provides complementary blood-pressure control and is used when single-agent therapy is inadequate or when fixed-dose convenience is preferred (U.S. Food and Drug Administration [FDA], 2024a).
When did valsartan and hydrochlorothiazide lose exclusivity?
The combination lost meaningful U.S. market exclusivity years ago. Diovan HCT is no longer protected by an active commercial exclusivity period that prevents ANDA competition.
The original valsartan product patents expired in the early 2010s. Any remaining patent rights associated with the original branded product do not create a practical barrier to routine generic entry in the United States. Generic valsartan and hydrochlorothiazide products have been marketed for years through multiple manufacturers.
Key exclusivity timeline
| Milestone | Approximate timing | Commercial effect |
|---|---|---|
| Diovan HCT introduced | Late 1990s | Created the branded fixed-dose market |
| Core valsartan patent protection | Expired in the early 2010s | Removed the principal compound-level barrier |
| Generic combination entry | Early-to-mid 2010s | Began sustained price competition |
| Valsartan NDMA recall period | 2018 onward | Disrupted supply and increased regulatory scrutiny |
| Current position | 2024-2025 | Mature generic market with no meaningful brand exclusivity |
The product’s commercial lifecycle therefore follows the standard pattern for mature oral antihypertensives: premium pricing during patent protection, rapid generic substitution after expiry, then stable but low-margin demand.
What patents protect valsartan and hydrochlorothiazide?
No commercially significant U.S. patent estate currently protects the basic valsartan/hydrochlorothiazide combination from generic competition.
The principal patent categories historically associated with the product were:
- Valsartan compound patents.
- Fixed-dose combination patents.
- Formulation and dosage-form patents.
- Method-of-use claims covering treatment of hypertension or cardiovascular disease.
- Pediatric or regulatory exclusivity associated with the reference product.
The compound-level rights are expired. Any residual patents that once covered specific formulations, dosage schedules, or uses are not sufficient to preserve branded market control over ordinary generic tablets.
What formulations are protected by valsartan and hydrochlorothiazide patents?
The commercially important formulation is an immediate-release oral tablet. It does not require an extended-release delivery system, complex device, sterile manufacturing process, or biologic production platform.
Generic manufacturers typically compete through:
- Tablet strength selection.
- Excipients and dissolution performance.
- Manufacturing scale.
- Packaging and bottle configurations.
- Stability data.
- Supply-chain reliability.
- Contracting with wholesalers, pharmacy benefit managers, and retail pharmacies.
Formulation differences can support ANDA-specific intellectual property or regulatory certifications, but they generally do not provide durable market exclusivity for the base combination.
What is the Orange Book status of Diovan HCT?
Diovan HCT is an older small-molecule reference product whose commercial protection has expired. The FDA Orange Book remains relevant for identifying the reference listed drug, approved strengths, therapeutic equivalence codes, and any patent or exclusivity listings associated with the product.
For business purposes, the key Orange Book conclusion is that Diovan HCT is an ANDA-accessible product. Generic manufacturers do not need to develop a new clinical efficacy program. They generally demonstrate pharmaceutical equivalence, bioequivalence, manufacturing compliance, and conformance with FDA quality requirements.
The absence of meaningful current exclusivity means that an applicant’s main barriers are operational rather than legal:
- FDA approval timing.
- Ability to source valsartan and hydrochlorothiazide API.
- Compliance with current good manufacturing practices.
- Capacity to withstand price reductions.
- Stable supply during recalls or API disruptions.
Which companies compete in valsartan and hydrochlorothiazide?
Competition is fragmented across generic manufacturers. Companies that have marketed valsartan-containing products in the United States have included large multinational and specialty-generic firms such as Teva, Mylan/Viatris, Solco Healthcare, Torrent Pharmaceuticals, Aurobindo Pharma, Lupin, and other ANDA holders, depending on strength and market period.
The exact competitive set changes because generic companies periodically:
- Withdraw low-margin products.
- Transfer ANDAs.
- Consolidate manufacturing sites.
- Exit products after warning letters or recalls.
- Reprice products in response to wholesaler contracts.
- Replace affected API suppliers.
The reference brand has little ability to maintain a premium unless it offers reliable supply, contracting advantages, or a differentiated channel strategy. In a mature fixed-dose combination, retail pharmacy substitution usually favors the lowest-cost therapeutically equivalent product that has dependable availability.
How does valsartan and hydrochlorothiazide compare with competing antihypertensive combinations?
| Product class | Examples | Patent position | Commercial profile |
|---|---|---|---|
| Valsartan/HCTZ | Diovan HCT and generics | Expired | Generic, price-sensitive |
| Losartan/HCTZ | Hyzaar and generics | Expired | Broad generic competition |
| Irbesartan/HCTZ | Avalide and generics | Expired | Mature generic market |
| Olmesartan/HCTZ | Benicar HCT and generics | Expired or largely expired | Some branded legacy demand |
| Telmisartan/HCTZ | Micardis HCT and generics | Expired | Smaller, differentiated prescriber base |
| ACE inhibitor/thiazide combinations | Lisinopril/HCTZ, enalapril/HCTZ | Expired | High-volume generic alternatives |
Valsartan/HCTZ competes in a crowded therapeutic category. Losartan/HCTZ and lisinopril/HCTZ generally exert the greatest substitution pressure because of broad physician familiarity, extensive generic availability, and low acquisition cost.
What patent litigation affects valsartan and hydrochlorothiazide?
There is no current major U.S. patent litigation blocking generic access to valsartan/hydrochlorothiazide. Historical litigation involving valsartan products was more important during the patent-protected period and in disputes involving other valsartan formulations or related products.
The most consequential recent legal and regulatory event was not patent litigation. It was the 2018 discovery of nitrosamine contamination in certain valsartan API supplies, followed by recalls and investigations involving manufacturers and suppliers.
FDA identified N-nitrosodimethylamine, or NDMA, in valsartan supplied by Zhejiang Huahai Pharmaceuticals. The contamination was associated with changes in manufacturing processes and affected products from multiple manufacturers. FDA and other regulators expanded testing to related sartan products and later addressed additional nitrosamine impurities, including N-nitrosodiethylamine, or NDEA, in some products (FDA, 2018; FDA, 2024b).
What regulatory risks affect the product?
The principal regulatory risk is manufacturing quality, not clinical efficacy or patent validity.
Nitrosamine and API-supply risk
The valsartan recalls created several business consequences:
- Temporary withdrawal of affected lots.
- Retail and wholesaler shortages.
- Supplier qualification expenses.
- Increased analytical testing.
- Greater FDA scrutiny of API manufacturing.
- Potential switching to alternative ARBs.
- Reputational damage for affected manufacturers.
The recalls did not eliminate the valsartan/hydrochlorothiazide market. They redistributed volume among manufacturers with unaffected API sources and acceptable regulatory records.
FDA approval and substitution
Generic applicants must show that their product is pharmaceutically equivalent and bioequivalent to the reference listed drug. State substitution rules and payer formularies determine how quickly prescriptions migrate from branded or higher-priced products to lower-cost generics.
Because the product is an immediate-release tablet with established active ingredients, regulatory development is less expensive than for a new chemical entity. The main development cost is associated with formulation, analytical work, stability, bioequivalence, facility readiness, and ANDA review.
How strong is the patent estate for valsartan and hydrochlorothiazide?
The patent estate is weak from a market-exclusion perspective.
| Patent factor | Assessment |
|---|---|
| Compound patent | Expired |
| Fixed-dose combination protection | Expired or commercially non-blocking |
| Formulation protection | Limited practical value |
| Method-of-use protection | Not a meaningful barrier to ordinary generic hypertension treatment |
| Regulatory exclusivity | Expired |
| Biosimilar protection | Not applicable |
| Generic substitution risk | High |
| Litigation leverage | Low |
A generic manufacturer’s defensibility is more likely to come from operational execution than from patents. Manufacturing scale, validated suppliers, FDA-compliant facilities, and reliable distribution have greater economic value than incremental patent filings.
What generic entry risks exist for valsartan and hydrochlorothiazide?
Generic entry risk is effectively realized rather than prospective. The market has already experienced broad generic penetration.
For an incumbent manufacturer, the main risks are:
- Further price compression as additional ANDA holders enter.
- Loss of formulary placement.
- API shortages or contamination events.
- FDA warning letters or manufacturing injunctions.
- Product recalls.
- Wholesaler concentration.
- Substitution by other ARB/thiazide combinations.
- Declining use of fixed-dose combinations in favor of separate tablets or newer antihypertensive regimens.
For a new entrant, approval alone does not ensure attractive returns. Mature generic markets can support many approved suppliers but only a smaller number of economically viable producers.
What is the financial trajectory for valsartan and hydrochlorothiazide?
The financial trajectory is mature, low-growth, and volume-dependent. The product is unlikely to generate material brand-level revenue comparable with patent-protected cardiovascular drugs. Revenue is distributed among multiple generic manufacturers, and public companies generally report valsartan/hydrochlorothiazide within broader generic portfolios rather than as a separately disclosed product.
Revenue profile by lifecycle stage
| Lifecycle stage | Pricing | Volume | Margin profile |
|---|---|---|---|
| Branded exclusivity | High | Growing | High |
| Early generic entry | Falling rapidly | Expanding | Initially attractive, then compressing |
| Mature generic market | Low | Stable or declining | Low to moderate |
| Supply disruption | Volatile | Temporarily constrained | Can improve for unaffected suppliers |
| Long-term outlook | Persistently low | Stable hypertension demand | Dependent on scale and cost control |
The underlying disease market remains large because hypertension is chronic and prevalent. That does not translate into high product revenue. Patients can be treated with numerous inexpensive alternatives, and payers generally favor the lowest-cost therapeutically equivalent option.
What drives manufacturer profitability?
Profitability depends on four variables:
- Net selling price after rebates and wholesaler discounts.
- Annual prescription volume.
- Cost of API and finished-dose manufacturing.
- Product availability and recall history.
A manufacturer with a low-cost API source and high utilization at an efficient facility can earn acceptable returns even at low unit prices. A smaller producer with expensive third-party manufacturing may face poor economics despite steady demand.
Does the drug have significant revenue exposure?
Valsartan/hydrochlorothiazide has limited standalone revenue exposure for diversified pharmaceutical companies. It can matter more for smaller generic companies whose portfolios include a concentrated group of cardiovascular products.
The product’s revenue can temporarily increase during supply disruptions affecting competitors. That benefit is usually reversible. Once recalled or constrained suppliers return, pricing pressure typically resumes.
How did the 2018 valsartan recall change the market?
The recall temporarily changed the competitive balance by making supply reliability a commercial differentiator. Companies with unaffected API sources gained prescription and distributor volume. The event also increased the cost of compliance across the sartan category.
The recall did not create lasting exclusivity. It changed supplier economics and regulatory expectations:
- API traceability became more important.
- Manufacturers increased impurity testing.
- Regulators scrutinized process changes more closely.
- Buyers placed greater value on dual sourcing.
- Some patients and clinicians switched to other ARBs.
FDA later established broader controls for nitrosamine impurities and developed analytical methods and regulatory expectations applicable to multiple drug classes (FDA, 2024b).
What licensing deals affect valsartan and hydrochlorothiazide?
There is no widely reported current licensing transaction that materially controls the U.S. valsartan/hydrochlorothiazide market. The original commercial rights were associated with Novartis and its Diovan franchise. The present market is primarily driven by ANDA ownership, manufacturing arrangements, API sourcing, and distribution contracts.
Licensing or supply transactions can still occur at the product level through:
- ANDA transfers.
- Contract manufacturing agreements.
- API supply contracts.
- Regional commercialization rights.
- Authorized-generic arrangements.
These transactions are operational rather than strategic platform deals. Their value depends on approved manufacturing capacity and reliable supply, not on proprietary pharmacology.
What is the outlook for generic launch scenarios?
A new U.S. generic launch would enter a highly competitive market with limited patent risk and substantial price risk.
Likely launch scenarios
| Scenario | Expected market effect |
|---|---|
| One additional entrant with reliable supply | Modest incremental price erosion |
| Multiple entrants at the same strengths | Faster price compression |
| Entrant launches after competitor recall | Temporary volume opportunity |
| Entrant relies on a single API source | Elevated supply risk |
| Entrant launches a less common strength | Potentially narrower competition |
| Brand relaunch at premium pricing | Limited unless supported by supply or payer differentiation |
The strongest commercial opportunity is not a novel formulation. It is dependable supply in strengths with persistent prescription demand and limited current availability. That opportunity remains vulnerable to rapid entry by other ANDA holders.
What are the geographic market dynamics?
The United States is a mature generic market with intense payer and pharmacy substitution. Europe and other regulated markets also have broad generic access, but prices, reference-pricing systems, tender structures, and regulatory requirements vary by country.
Emerging markets can have larger volume growth but lower unit prices and greater exposure to local manufacturing rules, public procurement, currency movement, and distributor concentration. Valsartan/hydrochlorothiazide is not geographically protected by a differentiated delivery system, so local competition tends to develop wherever regulatory approval and API access are available.
What manufacturing and intellectual-property barriers remain?
The remaining barriers are practical:
- Validated production capacity.
- Consistent API quality.
- Nitrosamine control.
- Bioequivalence and dissolution performance.
- FDA inspection readiness.
- Stability across commercial packaging.
- Reliable distribution.
- Ability to operate at low gross margins.
The intellectual-property barrier is low. Manufacturing quality and supply-chain resilience are the main determinants of sustainable market participation.
Key Takeaways
- Valsartan and hydrochlorothiazide is a mature, generic-dominated antihypertensive combination.
- Diovan HCT no longer has commercially meaningful U.S. exclusivity.
- Core valsartan patent protection expired in the early 2010s.
- The product is subject to ANDA competition and ordinary generic substitution.
- No biosimilar risk applies because the product is a small-molecule drug.
- The 2018 valsartan NDMA recalls created supply disruption but did not restore exclusivity.
- Revenue is volume-driven and generally not separately disclosed by diversified manufacturers.
- Generic profitability depends on API cost, manufacturing scale, supply reliability, and contracting.
- Competitive risk is high, while patent litigation risk is low.
- The long-term market outlook is stable in demand but structurally pressured on price.
FAQs About Valsartan and Hydrochlorothiazide Market Exclusivity
Is valsartan and hydrochlorothiazide still under patent?
No commercially significant U.S. patent protection prevents generic competition. The core valsartan patent estate expired years ago.
Is Diovan HCT still sold as a branded product?
Diovan HCT may remain listed or available through certain channels, but the U.S. market is primarily supplied by generic equivalents. Generic substitution and payer pricing limit branded commercial influence.
Can a generic manufacturer launch valsartan and hydrochlorothiazide without a clinical trial?
An applicant generally uses the ANDA pathway and must establish pharmaceutical equivalence and bioequivalence rather than repeat full clinical efficacy trials.
Did the valsartan recall affect hydrochlorothiazide?
The recall primarily involved contaminated valsartan API and finished products containing affected valsartan supplies. It did not mean that all hydrochlorothiazide products were contaminated or defective.
Which product competes most directly with valsartan and hydrochlorothiazide?
Losartan/hydrochlorothiazide is one of the closest direct competitors. Lisinopril/hydrochlorothiazide, irbesartan/hydrochlorothiazide, and olmesartan/hydrochlorothiazide also compete for the same hypertension treatment market.
References
- U.S. Food and Drug Administration. (2018). FDA updates on valsartan and ARB recalls. https://www.fda.gov
- U.S. Food and Drug Administration. (2024a). Diovan HCT prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024b). Nitrosamine impurity investigations and guidance. https://www.fda.gov
- U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
- DailyMed. (2024). Valsartan and hydrochlorothiazide tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
More… ↓
